Granulocytes in ocular HSV-1 infection: Opposing roles of mast cells and neutrophils

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 6, 2015, Pages 3763-3775

  Royer, Derek J ^a   Zheng, Min ^a   Conrady, Christopher D ^a   Carr, Daniel J J ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Cornea; Herpes simplex virus type 1; Innate immunity; Mast cell

Indexed keywords

CONCANAVALIN A; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; ICOSANOID; INTERLEUKIN 33; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANIMAL TISSUE; ARTICLE; CORNEAL PACHYMETRY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HISTOLOGY; IMMUNE RESPONSE; LEUKOSTASIS; MALE; MAST CELL; MICROSCOPY; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; C57BL MOUSE; HERPES SIMPLEX KERATITIS; IMMUNOLOGY;

ANIMALS; FEMALE; GRANULOCYTES; HERPESVIRUS 1, HUMAN; KERATITIS, HERPETIC; MALE; MAST CELLS; MICE; MICE, INBRED C57BL; NEUTROPHILS;

EID: 84939817428     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-16900     Document Type: Article

References (73)

1. Conrady CD, Drevets DA, Carr DJJ. Herpes simplex type I (HSV-1) infection of the nervous system: is an immune response a good thing? J Neuroimmunol. 2010;220:1-9.
2. Duan R, Vries RD de, Osterhaus ADME, Remeijer L, Verjans GM. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis. 2008;198:659-663.
3. Farooq AV, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol. 2012; 57:448-462.
4. Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2-United States, 1999-2010. J Infect Dis. 2014;209:325-333.
5. Inoue H, Motani-Saitoh H, Sakurada K, et al. Detection of varicella-zoster virus DNA in 414 human trigeminal ganglia from cadavers by the polymerase chain reaction: a comparison of the detection rate of varicella-zoster virus and herpes simplex virus type 1. J Med Virol. 2010;82:345-349.
6. Khanna KM, Lepisto AJ, Hendricks RL. Immunity to latent viral infection: many skirmishes but few fatalities. Trends Immunol. 2004;25:230-234.
7. Farooq AV, Valyi-Nagy T, Shukla D. Mediators and mechanisms of herpes simplex virus entry into ocular cells. Curr Eye Res. 2010;35:445-450.
8. Conrady CD, Zheng M, Mandal NA, van Rooijen N, Carr DJJ. IFN-α-driven CCL2 production recruits inflammatory monocytes to infection site in mice. Mucosal Immunol. 2013;6:45- 55.
9. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443:993-997.
10. Wuest TR, Carr DJJ. The role of chemokines during herpes simplex virus-1 infection. Front Biosci. 2008;13:4862-4872.
11. Tumpey TM, Cheng H, Yan XT, Oakes JE, Lausch RN. Chemokine synthesis in the HSV-1-infected cornea and its suppression by interleukin-10. J Leukoc Biol. 1998;63:486- 492.
12. Kenchegowda S, Bazan HEP. Significance of lipid mediators in corneal injury and repair. J Lipid Res. 2010;51:879-891.
13. Wojtasiak M, Pickett DL, Tate MD, et al. Depletion of Gr-1+, but not Ly6G+, immune cells exacerbates virus replication and disease in an intranasal model of herpes simplex virus type 1 infection. J Gen Virol. 2010;91(pt 9):2158-2166.
14. Wojtasiak M, Pickett DL, Tate MD, et al. Gr-1+ cells, but not neutrophils, limit virus replication and lesion development following flank infection of mice with herpes simplex virus type-1. Virology. 2010;407:143-151.
15. Frank GM, Buela K-AG, Maker DM, Harvey SAK, Hendricks RL. Early responding dendritic cells direct the local NK response to control herpes simplex virus 1 infection within the cornea. J Immunol. 2012;188:1350-1359.
16. Smelser GK, Silver S. The distribution of mast cells in the normal eye. Exp Eye Res. 1963;2:134-140.
17. Urb M, Sheppard DC. The role of mast cells in the defence against pathogens. PLoS Pathog. 2012;8:e1002619.
18. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010;10:440-452.
19. Wernersson S, Pejler G. Mast cell secretory granules: armed for battle. Nat Rev Immunol. 2014;14:478-494.
20. Miller HRP, Pemberton AD. Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut. Immunology. 2002;105:375-390.
21. Jahanyar J, Koerner MM, Loebe M, Youker KA, Torre-Amione G, Noon GP. The role of mast cells after solid organ transplantation. Transplantation. 2008;85:1365-1371.
22. Fijak M, Meinhardt A. The testis in immune privilege. Immunol Rev. 2006;213:66-81.
23. Anderson DF, Macleod JDA, Baddeley SM, et al. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leucocyte infiltration. Clin Exp Allergy. 1997;27:1060-1066.
24. Williams RM, Singh J, Sharkey KA. Innervation and mast cells of the rat exorbital lacrimal gland: the effects of age. J Auton Nerv Syst. 1994;47:95-108.
25. Iwamoto T, Smelser GK. Electron microscope studies on the mast cells and blood and lymphatic capillaries of the human corneal limbus. Invest Ophthalmol. 1965;4:815-834.
26. Tharp MD, Seelig LL Jr, Tigelaar RE, Bergstresser PR. Conjugated avidin binds to mast cell granules. J Histochem Cytochem. 1985;33:27-32.
27. Li X, Gu X, Boyce TM, et al. Caveolin-1 increases proinflammatory chemoattractants and blood-retinal barrier breakdown but decreases leukocyte recruitment in inflammation. Invest Ophthalmol Vis Sci. 2014;55:6224-6234.
28. Conrady CD, Zheng M, Fitzgerald KA, Liu C, Carr DJJ. Resistance to HSV-1 infection in the epithelium resides with the novel innate sensor, IFI-16. Mucosal Immunol. 2012;5: 173-183.
29. Feduchi E, Carrasco L. Mechanism of inhibition of HSV-1 replication by tumor necrosis factor and interferon gamma. Virology. 1991;180:822-825.
30. Sharif NA, Wiernas TK, Griffin BW, Davis TL. Pharmacology of [3H]-pyrilamine binding and of the histamine-induced inositol phosphates generation, intracellular Ca2+-mobilization and cytokine release from human corneal epithelial cells. Br J Pharmacol. 1998;125:1336-1344.
31. Wuest T, Austin BA, Uematsu S, et al. Intact TRL 9 and type I interferon signaling pathways are required to augment HSV-1 induced corneal CXCL9 and CXCL10. J Neuroimmunol. 2006; 179:46-52.
32. Matsuba-Kitamura S, Yoshimoto T, Yasuda K, et al. Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis. Int Immunol. 2010;22:479-489.
33. Alves-Filho JC, Sônego F, Souto FO, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med. 2010;16:708-712.
34. Roy A, Ganesh G, Sippola H, et al. Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation. J Biol Chem. 2014;289:237-250.
35. Doener F, Michel A, Reuter S, et al. Mast cell-derived mediators promote murine neutrophil effector functions. Int Immunol. 2013;25:553-561.
36. Nigrovic PA, Gray DHD, Jones T, et al. Genetic inversion in mast cell-deficient (Wsh) mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. Am J Pathol. 2008; 173:1693-1701.
37. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9: 162-174.
38. Michel A, Schüler A, Friedrich P, et al. Mast cell-deficient Kit(W-sh) "Sash" mutant mice display aberrant myelopoiesis leading to the accumulation of splenocytes that act as myeloidderived suppressor cells. J Immunol. 2013;190:5534-5544.
39. Mantelli F, Calder VL, Bonini S. The anti-inflammatory effects of therapies for ocular allergy. J Ocul Pharmacol Ther. 2013; 29:786-793.
40. Xu X, Zhang D, Zhang H, et al. Neutrophil histamine contributes to inflammation in mycoplasma pneumonia. J Exp Med. 2006;203:2907-2917.
41. Chazot PL. Histamine pharmacology: four years on. Br J Pharmacol. 2013;170:1-3.
42. Cíž M, Lojek A. Modulation of neutrophil oxidative burst via histamine receptors. Br J Pharmacol. 2013;170:17-22.
43. Tumpey TM, Chen SH, Oakes JE, Lausch RN. Neutrophilmediated suppression of virus replication after herpes simplex virus type 1 infection of the murine cornea. J Virol. 1996;70: 898-904.
44. Piliponsky AM, Chen C-C, Rios EJ, et al. The chymase mouse mast cell protease 4 degrades TNF, limits inflammation, and promotes survival in a model of sepsis. Am J Pathol. 2012;181: 875-886.
45. Hayashi T, Yao S, Crain B, et al. Mast cell-mediated inhibition of abdominal neutrophil inflammation by a PEGylated TLR7 ligand. Mediators Inflamm. 2012;2012:262394.
46. Stock AT, Smith JM, Carbone FR. Type I IFN suppresses Cxcr2 driven neutrophil recruitment into the sensory ganglia during viral infection. J Exp Med. 2014;211:751-759.
47. Dietrich N, Rohde M, Geffers R, et al. Mast cells elicit proinflammatory but not type I interferon responses upon activation of TLRs by bacteria. Proc Natl Acad Sci U S A. 2010; 107:8748-8753.
48. Reichel CA, Rehberg M, Lerchenberger M, et al. Ccl2 and Ccl3 mediate neutrophil recruitment via induction of protein synthesis and generation of lipid mediators. Arterioscler Thromb Vasc Biol. 2009;29:1787-1793.
49. Xue M-L, Thakur A, Cole N, et al. A critical role for CCL2 and CCL3 chemokines in the regulation of polymorphonuclear neutrophils recruitment during corneal infection in mice. Immunol Cell Biol. 2007;85:525-531.
50. Lundstrom SL, Saluja R, Adner M, Haeggstrom JZ, Nilsson G, Wheelock CE. Lipid mediator metabolic profiling demonstrates differences in eicosanoid patterns in two phenotypically distinct mast cell populations. J Lipid Res. 2013;54:116-126.
51. Rajasagi NK, Reddy PBJ, Suryawanshi A, Mulik S, Gjorstrup P, Rouse BT. Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1. J Immunol. 2011;186:1735-1746.
52. Lee J-E, Sun Y, Gjostrup P, Pearlman E. Inhibition of corneal inflammation by the resolvin E1. Invest Ophthalmol Vis Sci. 2015;56:2728-2736.
53. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007;447:869-874.
54. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510:92-101.
55. Mayer-Barber KD, Andrade BB, Oland SD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature. 2014;511:99-103.
56. Pazos MA, Pirzai W, Yonker LM, Morisseau C, Gronert K, Hurley BP. Distinct cellular sources of hepoxilin A3 and leukotriene B4 are used to coordinate bacterial-induced neutrophil transepithelial migration. J Immunol. 2015;194: 1304-1315.
57. Mrsny RJ, Gewirtz AT, Siccardi D, et al. Identification of hepoxilin A3 in inflammatory events: a required role in neutrophil migration across intestinal epithelia. Proc Natl Acad Sci U S A. 2004;101:7421-7426.
58. Srinivasan BD, Kulkarni PS. The role of arachidonic acid metabolites in the mediation of the polymorphonuclear leukocyte response following corneal injury. Invest Ophthalmol Vis Sci. 1980;19:1087-1093.
59. Birkle DL, Sanitato JJ, Kaufman HE, Bazan NG. Arachidonic acid metabolism to eicosanoids in herpes virus-infected rabbit cornea. Invest Ophthalmol Vis Sci. 1986;27:1443-1446.
60. Sarashina H, Tsubosaka Y, Omori K, et al. Opposing immunomodulatory roles of prostaglandin D2 during the progression of skin inflammation. J Immunol. 2014;192:459- 465.
61. Rajakariar R, Hilliard M, Lawrence T, et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxy 12-14 PGJ2. Proc Natl Acad Sci U S A. 2007;104:20979-20984.
62. Zarbock A, Distasi MR, Smith E, et al. Improved survival and reduced vascular permeability by eliminating or blocking 12/ 15-lipoxygenase in mouse models of acute lung injury (ALI). J Immunol. 2009;183:4715-4722.
63. Rossaint J, Nadler JL, Ley K, Zarbock A. Eliminating or blocking 12/15-lipoxygenase reduces neutrophil recruitment in mouse models of acute lung injury. Crit Care. 2012;16:R166.
64. Murata T, Aritake K, Matsumoto S, et al. Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proc Natl Acad Sci U S A. 2011;108:19802-19807.
65. Murata T, Aritake K, Tsubosaka Y, et al. Anti-inflammatory role of PGD2 in acute lung inflammation and therapeutic application of its signal enhancement. Proc Natl Acad Sci U S A. 2013;110:5205-5210.
66. Carr DJJ, Chodosh J, Ash J, Lane TE. Effect of anti-CXCL10 monoclonal antibody on herpes simplex virus type 1 keratitis and retinal infection. J Virol. 2003;77:10037-10046.
67. Pillay J, Tak T, Kamp VM, Koenderman L. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell Mol Life Sci. 2013;70: 3813-3827.
68. Youn J-I, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 2012; 91:167-181.
69. Tsiganov EN, Verbina EM, Radaeva TV, et al. Gr-1dimCD11b+ immature myeloid-derived suppressor cells but not neutrophils are markers of lethal tuberculosis infection in mice. J Immunol. 2014;192:4718-4727.
70. Norris BA, Uebelhoer LS, Nakaya HI, Price AA, Grakoui A, Pulendran B. Chronic but not acute virus infection induces sustained expansion of myeloid suppressor cell numbers that inhibit viral-specific T cell immunity. Immunity. 2013;38:309- 321.
71. Kumar A, Zhang J, Yu F-SX Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells. Immunology. 2006;117:11-21.
72. Jin X, Qin Q, Chen W, Qu J. Expression of toll-like receptors in the healthy and herpes simplex virus-infected cornea. Cornea. 2007;26:847-852.
73. Hara Y, Shiraishi A, Kobayashi T, et al. Alteration of TLR3 pathways by glucocorticoids may be responsible for immunosusceptibility of human corneal epithelial cells to viral infections. Mol Vis. 2009;15:937-948.